Sylvain Poujol

969 total citations
36 papers, 796 citations indexed

About

Sylvain Poujol is a scholar working on Oncology, Molecular Biology and Surgery. According to data from OpenAlex, Sylvain Poujol has authored 36 papers receiving a total of 796 indexed citations (citations by other indexed papers that have themselves been cited), including 21 papers in Oncology, 11 papers in Molecular Biology and 6 papers in Surgery. Recurrent topics in Sylvain Poujol's work include Cancer Treatment and Pharmacology (9 papers), Cancer therapeutics and mechanisms (8 papers) and Colorectal Cancer Treatments and Studies (6 papers). Sylvain Poujol is often cited by papers focused on Cancer Treatment and Pharmacology (9 papers), Cancer therapeutics and mechanisms (8 papers) and Colorectal Cancer Treatments and Studies (6 papers). Sylvain Poujol collaborates with scholars based in France, Belgium and United States. Sylvain Poujol's co-authors include Frédéric Pinguet, Françoise Bressolle, Mahfoud Boustta, Michel Vert, Pierre‐Emmanuel Colombo, Marc Ychou, Cécile Astre, C. Astre, Gilles Romieu and Stéphane Culine and has published in prestigious journals such as Journal of Clinical Oncology, Journal of Controlled Release and British Journal of Cancer.

In The Last Decade

Sylvain Poujol

36 papers receiving 780 citations

Peers

Sylvain Poujol
Varun Khurana United States
Leyuan Xu United States
Longzhu Piao United States
Lê Thị Thanh Thủy Japan
Xiaorong Qi China
Shu Li China
E. M. Molnar Hungary
Sachin Mittal India
Maha M. Amin Egypt
Yonghua Wang China
Varun Khurana United States
Sylvain Poujol
Citations per year, relative to Sylvain Poujol Sylvain Poujol (= 1×) peers Varun Khurana

Countries citing papers authored by Sylvain Poujol

Since Specialization
Citations

This map shows the geographic impact of Sylvain Poujol's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sylvain Poujol with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sylvain Poujol more than expected).

Fields of papers citing papers by Sylvain Poujol

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sylvain Poujol. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sylvain Poujol. The network helps show where Sylvain Poujol may publish in the future.

Co-authorship network of co-authors of Sylvain Poujol

This figure shows the co-authorship network connecting the top 25 collaborators of Sylvain Poujol. A scholar is included among the top collaborators of Sylvain Poujol based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sylvain Poujol. Sylvain Poujol is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Assénat, Eric, Georges‐Philippe Pageaux, Simon Thézenas, et al.. (2019). Sorafenib alone vs. sorafenib plus GEMOX as 1st-line treatment for advanced HCC: the phase II randomised PRODIGE 10 trial. British Journal of Cancer. 120(9). 896–902. 42 indexed citations
2.
Sénesse, Pierre, Nicolas Flori, Sylvain Poujol, et al.. (2017). Management of Cancer Cachexia and Guidelines Implementation in a Comprehensive Cancer Center: A Physician-Led Cancer Nutrition Program Adapted to the Practices of a Country. Journal of Pain and Symptom Management. 54(3). 387–393.e3. 13 indexed citations
3.
Samalin, Emmanuelle, Olivier Bouché, Simon Thézenas, et al.. (2014). Sorafenib and irinotecan (NEXIRI) as second- or later-line treatment for patients with metastatic colorectal cancer and KRAS-mutated tumours: a multicentre Phase I/II trial. British Journal of Cancer. 110(5). 1148–1154. 44 indexed citations
4.
Boustta, Mahfoud, et al.. (2013). Versatile UCST-based thermoresponsive hydrogels for loco-regional sustained drug delivery. Journal of Controlled Release. 174. 1–6. 103 indexed citations
5.
Kluger, Nicolas, William Jacot, É. Frouin, et al.. (2012). Permanent scalp alopecia related to breast cancer chemotherapy by sequential fluorouracil/epirubicin/cyclophosphamide (FEC) and docetaxel: a prospective study of 20 patients. Annals of Oncology. 23(11). 2879–2884. 57 indexed citations
6.
Poujol, Sylvain, Françoise Bressolle, Isabelle Solassol, & Frédéric Pinguet. (2012). Stability of ready-to-use temsirolimus infusion solution (100 mg/L) in polypropylene containers under different storage conditions. Annales Pharmaceutiques Françaises. 70(3). 155–162. 3 indexed citations
7.
Poujol, Sylvain, et al.. (2012). Stability of the ready-to-use solutions of eribulin for intravenous infusion. Annales Pharmaceutiques Françaises. 70(5). 249–255. 4 indexed citations
8.
Mazard, Thibault, Marc Ychou, Simon Thézenas, et al.. (2011). Feasibility of biweekly combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in patients with metastatic solid tumors: results of a two-step phase I trial: XELIRI and XELIRINOX. Cancer Chemotherapy and Pharmacology. 69(3). 807–814. 6 indexed citations
9.
Raynal, Caroline, Jean‐Marc Pascussi, Cyril Breuker, et al.. (2010). Pregnane × Receptor (PXR) expression in colorectal cancer cells restricts irinotecan chemosensitivity through enhanced SN-38 glucuronidation. Molecular Cancer. 9(1). 46–46. 85 indexed citations
10.
11.
12.
Aldabbagh, Kaïs, Stéphane Pouderoux, Lise Roca, et al.. (2010). Etoposide, mitomycin, and methotrexate combination in heavily treated breast cancer: a retrospective study. Breast Cancer. 19(1). 16–22. 4 indexed citations
13.
14.
Duffour, Jacqueline, Sophie Gourgou, Françoise Desseigne, et al.. (2006). Multicentre phase II study using increasing doses of irinotecan combined with a simplified LV5FU2 regimen in metastatic colorectal cancer. Cancer Chemotherapy and Pharmacology. 60(3). 383–389. 16 indexed citations
15.
Solassol, Isabelle, et al.. (2005). Inter- and Intraindividual Variabilities in Pharmacokinetics of Fentanyl After Repeated 72-Hour Transdermal Applications in Cancer Pain Patients. Therapeutic Drug Monitoring. 27(4). 491–498. 51 indexed citations
16.
Poujol, Sylvain, Françoise Bressolle, Jacqueline Duffour, et al.. (2005). Pharmacokinetics and pharmacodynamics of irinotecan and its metabolites from plasma and saliva data in patients with metastatic digestive cancer receiving Folfiri regimen. Cancer Chemotherapy and Pharmacology. 58(3). 292–305. 18 indexed citations
17.
Fabbro, Michel, et al.. (2004). Population pharmacokinetics of melphalan, infused over a 24-hour period, in patients with advanced malignancies. Cancer Chemotherapy and Pharmacology. 53(6). 503–512. 28 indexed citations
18.
Pinguet, Frédéric, et al.. (2000). High-performance liquid chromatographic determination of vinorelbine in human plasma and blood: application to a pharmacokinetic study. Journal of Chromatography B Biomedical Sciences and Applications. 748(2). 389–399. 21 indexed citations
19.
Pinguet, Frédéric, et al.. (2000). SENSITIVE HIGH PERFORMANCE LIQUID CHROMATOGRAPHIC FLUORESCENCE DETERMINATION OF TOPOTECAN IN HUMAN PLASMA AND PAROTID SALIVA. Journal of Liquid Chromatography & Related Technologies. 23(15). 2373–2390. 2 indexed citations
20.
Martel, Pascal, Jean‐Claude Petit, Frédéric Pinguet, et al.. (1996). Long-term stability of 5-fluorouracil stored in PVC bags and in ambulatory pump reservoirs. Journal of Pharmaceutical and Biomedical Analysis. 14(4). 395–399. 19 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Varun Khurana Breakdown of academic impact, for papers by Leyuan Xu Breakdown of academic impact, for papers by Longzhu Piao Breakdown of academic impact, for papers by Lê Thị Thanh Thủy Breakdown of academic impact, for papers by Xiaorong Qi Breakdown of academic impact, for papers by Shu Li Breakdown of academic impact, for papers by E. M. Molnar Breakdown of academic impact, for papers by Sachin Mittal Breakdown of academic impact, for papers by Maha M. Amin Breakdown of academic impact, for papers by Yonghua Wang
Rankless by CCL
2026